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Accurate glomerular filtration rate estimation informs drug dosing and risk stratification.
Body composition heterogeneity influences creatinine production and the precision of cre-
atinine-based estimated glomerular filtration rate (eGFRcr) in the elderly. We compared
chronic kidney disease (CKD) categorization using eGFRcr and cystatin C-based esti-
mated GFR (eGFRcys) in an elderly, racially/ethnically diverse cohort to determine their
concordance.
Methods
The Northern Manhattan Study (NOMAS) is a predominantly elderly, multi-ethnic cohort
with a primary aim to study cardiovascular disease epidemiology. We included participants
with concurrently measured creatinine and cystatin C. eGFRcr was calculated using the
CKD-EPI 2009 equation. eGFRcys was calculated using the CKD-EPI 2012 equation. Logis-
tic regression was used to estimate odds ratios and 95% confidence intervals of factors
associated with reclassification from eGFRcr�60ml/min/1.73m2 to eGFRcys<60ml/min/
1.73m2.
Results
Participants (n = 2988, mean age 69±10yrs) were predominantly Hispanic, female, and
overweight/obese. eGFRcys was lower than eGFRcr by mean 23mL/min/1.73m2. 51% of par-
ticipants’ CKD status was discordant, and only 28% maintained the same CKD stage by
both measures. Most participants (78%) had eGFRcr�60mL/min/1.73m2; among these,
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64% had eGFRcys<60mL/min/1.73m2. Among participants with eGFRcr�60mL/min/1.73m2,
eGFRcys-based reclassification was more likely in those with age >65 years, obesity, current
smoking, white race, and female sex.
Conclusions
In a large, multiethnic, elderly cohort, we found a highly discrepant prevalence of CKD with
eGFRcys versus eGFRcr. Determining the optimal method to estimate GFR in elderly popula-
tions needs urgent further study to improve risk stratification and drug dosing.
Introduction
Accurate and reliable glomerular filtration rate (GFR) estimation has enabled the identifica-
tion and classification of renal dysfunction in a manner that could not be done with the use of
serum creatinine values in isolation.[1–3] The calculation of estimated GFR (eGFR) using cre-
atinine, an endogenous amino acid derivative of muscle cells, can inform drug dosing and
guide risk stratification.[4–6] By taking into account factors that impact creatinine generation,
eGFR equations are able to provide an assessment of GFR without the cost or complexity asso-
ciated with GFR “measurement” using exogenous substances such as inulin or iohexol.[7]
However, the use of creatinine is imperfect: because creatinine generation is dependent on
muscle mass, factors that influence body composition, including age, sex, and race, adversely
impact the reliability of creatinine-based GFR estimation.[8] Due to these limitations, Kidney
Disease Improving Global Outcomes (KDIGO) guidelines recommend confirming creatinine-
based chronic kidney disease (CKD) diagnosis using an alternative method of GFR estimation
in select groups.[9] In the United States, the widely-used MDRD (Modification of Diet in
Renal Disease) and CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equa-
tions were initially developed from cohorts with a low prevalence of socio-demographic char-
acteristics that may affect serum creatinine (mean age 50.6 years, 88% White and mean age 47
years, 95% White or Black race respectively).[10, 11]
Age-related body composition changes in the elderly lead to a decline in the relative pro-
portion of muscle mass and a corresponding decrease in creatinine production. In this setting,
stable renal function is reflected by decreasing serum creatinine concentrations over time, and
thus a decline in GFR may not be reflected by significant increases in serum creatinine.[12]
The uncertainty around creatinine-based estimates’ ability to adequately estimate GFR across
a variety of body compositions, particularly at the extremes of age, has led to interest in using
alternative biomarkers. Cystatin C is an endogenous protease inhibitor produced at a stable
rate by most nucleated cells, and its generation has less inter-person variability than that of cre-
atinine, especially as related to ethnicity, age, or sex.[8, 13, 14] Serum cystatin C values have
been shown to be predictive of mortality, and cystatin C-based GFR estimating (eGFRcys)
equations have been shown to outperform those using creatinine-based eGFR (eGFRcr) in pre-
diction of CKD-associated morbidity and mortality.[10, 15–20] Notably, although eGFRcys
does not significantly outperform eGFRcr in accuracy of GFR quantification in the general
population, there appears to be a greater advantage in the elderly.[21, 22] Further, while efforts
to develop new models for GFR estimation in the elderly have focused on European popula-
tions, the relative performance of creatinine- and cystatin-based equations remains unclear in
Hispanics, which is concerning given that this is the fastest growing segments of the United
States population.[21, 23, 24]
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The objectives of this study are to determine the concordance of cystatin- and creatinine-
based CKD diagnosis in the Northern Manhattan Study (NOMAS) cohort, an elderly, racially/
ethnically diverse cohort in northern Manhattan. Given that these demographic characteristics
were not well represented during the development of commonly used eGFR equations, we
hypothesized that there would be significant discordance in CKD prevalence when using the
two different GFR estimation methods.
Methods
Cohort
NOMAS is a prospective study with a primary aim to evaluate cardiovascular disease risk fac-
tors in an urban, racially/ethnically diverse community in northern Manhattan. Participants
were eligible for enrollment if they were age�40 years, had no prior history of stroke, had a
telephone, and resided in Northern Manhattan for 3 months prior to completion of an enroll-
ment phone interview.[25] All participants had serum creatinine measured at enrollment, and
a subsample (n = 2988, 90.6%) had cystatin C measurements on stored blood samples as part
of an ancillary study. All procedures performed were approved by and conducted in accor-
dance with the ethical standards of the Columbia University Medical Center’s Institutional
Review Board. Written informed consent was obtained from all participants.
Assessment of renal function, demographic variables, and risk factors
Blood samples were obtained during baseline enrollment (1993–2001). Creatinine and cysta-
tin C values were measured on samples obtained at the same time point (baseline enrollment)
for each patient. Laboratory testing was performed at Columbia University and the Univer-
sity of Miami. Serum creatinine (mg/dL) measurements used Olympus instrumentation with
a Jaffe-based method. Although initial creatinine concentrations were measured prior to
IDMS standardization, creatinine was re-measured in 100 samples stored at -80˚C using an
IDMS-traceable method for creatinine measurement in order to develop a correction factor
similar to what has been done successfully by other cohorts.[26, 27] The mean difference
between standardized and non-standardized creatinine was -0.056±0.079mg/dL (r = 0.98).
(S1 and S2 Figs). In the absence of a meaningful difference, a calibration factor was not
applied prior to using creatinine values for GFR estimation using the CKD-EPI 2009 equa-
tion.[28] However, a sensitivity analysis was performed by repeating the primary analysis
using creatinine values after calibration factor application. Cystatin C (mg/L) was measured
on samples (84% plasma, 14% serum, 2% unspecified) stored at -80˚C using Roche Diagnos-
tics Cystatin Reagents on a Roche analyzer, standardized against ERM-DA471/IFCC refer-
ence material (intra-assay coefficient of variation (CV) 2.8% and interassay CV 4.1%;
reference range 0.5–1.3 mg/L). The eGFRcys estimation was based on the CKD-EPI 2012
equation.[10]
Height and weight were measured during the initial patient assessment; overweight was
defined as BMI 25-30kg/m2 and obesity as BMI>30 kg/m2. Race, ethnicity, and smoking status
were self-reported. Hypertension was defined as systolic blood pressure >140mmHg or dia-
stolic blood pressure >90mmHg based on the mean of two blood pressure measurements or
the patient’s self-report of a history of hypertension/antihypertensive use. Diabetes mellitus
was defined by self-report, fasting blood glucose level>126mg/dL, or insulin/oral hypoglyce-
mic use. Hypercholesterolemia was based on self-report, lipid lowering therapy use, or fasting
total cholesterol level>240mg/dL.
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Statistical analysis
Calculated eGFRcr and eGFRcys were dichotomized at a clinical cutoff of 60ml/min/1.73m
2
consistent with standard GFR-based definitions of CKD (i.e., eGFR<60ml/min/1.73m2 =
CKD).[9] Discordance was defined as CKD diagnosis by only one of the two estimates. A
Bland-Altman analysis was used to assess agreement between eGFRcr and eGFRcys by plotting
the difference between the two estimates (eGFRcr—eGFRcys) against their mean ([eGFRcr +
eGFRcys]/2) for each participant. Reclassification was defined as change in eGFRcr-based CKD




2). Given the uncer-
tainty regarding which GFR estimate is more accurate in populations like ours and the absence
of measured GFR data, we chose this definition of reclassification because creatinine-based
GFR estimation is currently widely used in standard practice. We did, however, note that very
few participants had eGFRcr<60ml/min/1.73m
2 with eGFRcys>60ml/min/1.73m
2 and there-
fore focused our analysis of reclassification on participants with eGFRcr�60ml/min/1.73m
2.
We first assessed reclassification among those with eGFRcr�60ml/min/1.73m
2. The
proportion of reclassification was calculated and compared by baseline demographics and
comorbidities using multivariate logistic regression with indication of reclassification [1 for
reclassification (eGFRcys<60ml/min/1.73m
2) and 0 for no reclassification (eGFRcys�60ml/
min/1.73m2)] as a dependent variable. We calculated the odds ratio and 95% confidence inter-
val (OR, 95% CI) for the association with the proportion of reclassification. A similar analysis
was not performed on those with eGFRcr<60ml/min/1.73m
2 because only a small number
(n = 43) were reclassified with eGFRcys�60ml/min/1.73m
2; these participants were manually
reviewed.
We performed two sensitivity analyses. First, we rechecked the proportion of reclassifica-
tion using eGFRcr recalculated after applying a calibration factor to SCr values (based on
rechecking 100 samples using an IDMS-traceable method for creatinine, as above). Next, we
rechecked the proportion of reclassification only among participants with age<65 years who
self-identified as white race, a population more similar to the group in which the CKD-EPI
equations were originally developed. Finally, we calculated eGFR using the combined creati-
nine-cystatin CKD-EPI 2012 equation (eGFRcr-cys) to determine the difference in eGFR-based
CKD prevalence using each of the three estimates. Analyses were conducted using SAS version
9.3 (Cary, NC) and R version 3.5.0.
Results
Among the 3298 NOMAS cohort participants, 2988 (91%) had both serum creatinine and
cystatin C measured at the same time point and were included in our analysis. The mean age
of the final cohort was 69±10 years, with 61% individuals older than 65 years at the time of
data collection. Participants were predominantly Hispanic (53%), female (63%), and either
overweight (41%) or obese (28%) (Table 1).
Mean SCr was 0.96 ± 0.4mg/dL and mean cystatin C was 1.4 ± 0.6mg/L, corresponding to
mean eGFRcr 75 ± 19 ml/min/1.73m2 and mean eGFRcys 52 ± 17 ml/min/1.73m2. The creati-
nine- and cystatin-based GFR estimates (eGFRcr and eGFRcys, respectively) were correlated
(r = 0.62, p<0.001) (S3 and S4 Figs). On average, eGFRcys was 23±15ml/min/1.73m2 lower
than eGFRcr. The Bland-Altman plot shows that the participants primarily displayed differ-
ence between eGFRcr and eGFRcys of -7 to +53 (mean ± 2 standard deviations) with decreas-
ing agreement noted at higher mean eGFR (Fig 1). Accordingly, there was a markedly higher
prevalence of CKD (eGFR<60ml/min/1.73m2), using eGFRcys compared to eGFRcr (71% vs
22%, p<0.001) (Tables 2 and 3).
Creatinine- vs cystatin C-based GFR in NOMAS
PLOS ONE | https://doi.org/10.1371/journal.pone.0206839 November 14, 2018 4 / 14
The proportion of discordance between eGFRcr and eGFRcys-based CKD diagnosis was
51%. The highest discordance was observed among participants with eGFRcr�60ml/min/
1.73m2. Over half of the participants who were reclassified from eGFRcr�60ml/min/1.73 m
2 to
eGFRcys<60ml/min/1.73 m
2 had a difference in GFR estimates >30ml/min/1.73m2, while
only 2.8% of participants displayed a difference�10ml/min/1.73m2 (Table 4). Only 43 partici-
pants had eGFRcr<60ml/min/1.73 m
2 but eGFRcys>60ml/min/1.73 m
2; manual review
demonstrated that their GFR estimates were clustered around 60, with the majority (81%) dis-
playing eGFRcr 50–59.9 but eGFRcys 60–69.9 (median eGFR difference 9.9ml/min/1.73m
2).
49% of participants demonstrated CKD diagnosis concordance: 21% of the cohort had evi-
dence of CKD by both estimates, while 45 patients (1.5% of the cohort) had evidence of severe
CKD (eGFR<30ml/min/1.73m2) using both estimates. A minority of participants (28%) main-
tained the same CKD staging-based eGFR categories (ie.<15, 15–29, 30–59, 60–89,�90)
using both estimates (Tables 2 and 3).
Table 1. Baseline characteristics of cohort.















Never Smoker 1404 (47%)
Former Smoker 1084 (36%)
Current Smoker 498 (17%)
Comorbidities
Diabetes Mellitus 634 (21%)
Hypertension 2196 (73%)
Any Cardiac Disease 704 (24%)
Estimated GFR (ml/min/1.73m2)
eGFRcr, mean (sd) 75 ± 19
eGFRcys, mean (sd) 52 ± 17
Antihypertensive Use
Diuretic 465 (16%)
Beta blocker 355 (12%)
Calcium channel blocker 596 (20%)
ACE inhibitor 491 (16%)
sd = standard deviation, BMI = body mass index, GFR = glomerular filtration rate, eGFRcr = creatinine-based
estimated GFR using the CKD-EPI 2009 equation, eGFRcys = cystatin C-based estimated GFR using the CKD-EPI
2012 equation, ACE = angiotensin converting enzyme
https://doi.org/10.1371/journal.pone.0206839.t001
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Reclassification among eGFRcr�60ml/min/1.73m
2
Among those with eGFRcr�60ml/min/1.73m
2, the proportion of reclassification
(eGFRcys<60ml/min/1.73 m
2) was 64%. Reclassification was not limited to participants
with borderline eGFRcr—although those with eGFRcr 60-89ml/min/1.73m
2 were most
likely to be reclassified (76%), many participants with eGFRcr�90ml/min/1.73m
2 were
reclassified as well (38%). However, almost all (96%) of those reclassified were estimated to
have eGFRcys 30-59ml/min/1.73m
2. Most (81%) reclassified participants had �20mL/min/
1.73m2 discrepancy between GFR estimates.
Fig 1. Bland-Altman plot of the difference in creatinine-based estimated glomerular filtration rate (eGFRcr) and
cystatin C-based estimated glomerular filtration rate (eGFRcys) versus the mean of the two estimates.
https://doi.org/10.1371/journal.pone.0206839.g001
Table 2. Comparison of CKD diagnosis by equation.
eGFR (SCr) eGFR (Cys)
� 60 < 60 Total
� 60 838 1495 2333
(28.1%) (50%) (78.1%)
< 60 43 612 655
(1.4%) (20.5%) (21.9%)
Total 881 2107 2988
(29.5%) (70.5%)
CKD = chronic kidney disease, eGFR = estimated glomerular filtration rate
https://doi.org/10.1371/journal.pone.0206839.t002
Creatinine- vs cystatin C-based GFR in NOMAS
PLOS ONE | https://doi.org/10.1371/journal.pone.0206839 November 14, 2018 6 / 14
We examined the association of demographics and comorbidities with the proportion of
reclassification (Table 5). In an adjusted model, the odds of reclassification were greater in
those with age>65 years (vs. age�65, OR 5.67, 95% CI 4.61–6.99), obesity (OR 2.06 vs
BMI�30, 95% CI 1.64–2.59), current smokers (OR 1.66 vs non-smokers, 95% CI 1.26–2.18),
Table 3. Distribution of CKD stage by GFR-estimating equation.
eGFRcr eGFRcys Total
<15 15–29 30–59 60–89 �90 N %
<15 11 (92%) 1 (8%) 0 0 0 12 0.4
15–29 19 (56%) 14 (41%) 0 1 (3%) 0 34 1.1
30–59 10 (2%) 172 (28%) 385 (63%) 40 (7%) 1 (<1%) 608 20.4
60–89 2 (<1%) 48 (3%) 1181 (72%) 380 (23%) 19 (1%) 1630 54.5
� 90 0 8 (1%) 256 (36%) 402 (57%) 38 (5%) 704 23.6
Total 42 243 1822 823 58 2988
% 1.4 8.1 61 27.5 1.9
CKD = chronic kidney disease, eGFR = estimated glomerular filtration rate
https://doi.org/10.1371/journal.pone.0206839.t003










CKD = chronic kidney disease, eGFR = estimated glomerular filtration rate
https://doi.org/10.1371/journal.pone.0206839.t004
Table 5. Factors associated with reclassification to eGFRcys <60 among participants with eGFRcr�60.
Parameter Adjusted�
OR 95% CI
Age>65 5.67 4.61 6.99
Female (vs Male) 1.56 1.27 1.92
African American (vs. White) 0.49 0.36 0.67
Hispanic (vs. White) 0.64 0.48 0.85
Diabetics 0.61 0.48 0.77
Hypertension 1.24 1.00 1.54
Obese 2.06 1.63 2.59
Past Smoker (vs. non-smoker) 1.08 0.87 1.35
Current Smoker (vs. non-smoker) 1.66 1.26 2.18
Hypercholesterolemia 0.93 0.76 1.14
Any Cardiac Disease 1.73 1.35 2.23
OR = odds ratio, CI = confidence interval;
�Adjusted for age, sex, race-ethnicity, education, medical insurance, diabetes, hypertension, BMI, smoking status,
hypercholesterolemia and cardiac disease
https://doi.org/10.1371/journal.pone.0206839.t005
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non-diabetics (OR 1.64, 95% CI 1.30–2.08), females (OR 1.56, 95% CI 1.27–1.92), and white
race (vs. African American, OR 2.04, 95% CI 1.49–2.78) (vs. Hispanic, OR 1.56, 95% CI 1.18–
2.08).
Sensitivity analyses
Applying the calibration factor to serum creatinine values as described above yielded similar
reclassification frequency (S1 Table). Next, we limited the analysis to participants aged <65
years with white race. These 110 participants continued to display a high frequency of reclassi-
fication: among the 88% of this subpopulation with eGFRcr�60ml/min/1.73m
2, 49% were
reclassified to eGFRcys<60ml/min/1.73m
2 (S2 Table). Finally, given the large difference in
CKD prevalence observed above, we calculated eGFRcr-cys using the CKD-EPI 2012 formula
that utilizes both biomarkers in a post-hoc analysis. Expectedly, we found that this method of
GFR estimation yielded a CKD prevalence in between those provided using eGFRcr and
eGFRcys (54.8%) (S3 Table).
Discussion
We compared creatinine- and cystatin-based GFR estimation in a large, elderly, racially/ethni-
cally diverse cohort and found a large difference in the prevalence of CKD (defined as
eGFR<60ml/min/1.73m2). While the direction of the findings was consistent with our hypoth-
esis, the magnitude of the differences was striking. Over half of the participants did not retain
the same CKD status using both GFR estimates, and the differences in CKD classification
using eGFRcys and eGFRcr were not simply clustered around CKD class thresholds. In fact,
even among participants with eGFRcr�90ml/min/1.73m
2 (classically considered a “normal”
GFR), 37.5% were reclassified as having CKD using eGFRcys. This degree of discordance is
greater than has been observed in other cohorts and raises potential concerns about the com-
monly used creatinine- and cystatin-based GFR estimates. The widely-used CKD-EPI eGFR
equations were developed in a population with a median age of 47 years and only <4% of
participants were aged�71 years.[28] In contrast, the mean participant age at the time of
enrollment in NOMAS was 69 years. Further, over half of our participants self-identified as
Hispanic. The cystatin C-based CKD-EPI eGFR equation may have an advantage in our cohort
given the absence of inclusion of race and a smaller impact of age on the estimate.[10, 14]
Previous studies have compared creatinine- and cystatin-based eGFR in different elderly
groups but have not demonstrated the degree of discordance that we observed.[29–32] The
Sacramento Area Latino Study on Aging (SALSA), a cohort of Mexican-American participants
with mean age 71 years, demonstrated that 10% of participants had discordant eGFRcr vs
eGFRcys CKD classification.[29] However, the SALSA cohort had a much lower prevalence of
CKD compared to the NOMAS cohort, with only 21% of participants having CKD based on
any marker (whereas in our group 22% and 71% had CKD based on creatinine and cystatin C,
respectively).[29] A smaller study comparing GFR estimates in 95 elderly Brazilian participants
Brazil (mean age 85.3 years) suggested that although eGFRcr overestimated GFR, eGFRcys was
more biased than eGFRcr, and the combined use of both markers performed better.[33] Simi-
larly, estimating GFR with a combined creatinine and cystatin equation outperformed eGFRcys
and eGFRcr in an elderly Icelandic cohort (n = 805, mean age 80.3 years).[32] A portion of
another analysis with participants of primarily European ancestry (n = 394, mean age 80 years)
found that while both equations overestimated GFR in those without decreased measured
GFR, eGFRcys tended to underestimate GFR in patients with measured GFR<60ml/min/
1.73m2, while eGFRcr overestimated GFR in the same group.[34] An additional study exam-
ined reclassification among participants in the Osteoporotic Fractures in Men Study (mean
Creatinine- vs cystatin C-based GFR in NOMAS
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age 76.4 years) and found a large discrepancy between prevalence of eGFR<60ml/min/1.73m2
based on eGFRcys and eGFRcr (36% vs 23%), with eGFRcys providing superior prediction of
mortality.[35]
The magnitude of the difference between the equations demonstrated in our study is large
and, given the implications for incorrect medication dosing, particularly concerning. Our
prevalence of eGFRcys-based CKD is consistent with prior data that used the creatinine-based
Modification of Diet in Renal Disease (MDRD) Study formula and noted prevalent CKD
Stages 1–4 in almost half of NHANES 1999–2004 participants age�70 years, with 37.8% of
participants in this age group having CKD stages 3 or 4.[36, 37] Further, that analysis also
showed a significant increase in CKD prevalence over time, supporting the plausibility of our
findings.[36] The large discrepancies we observed in the absence of measured GFR data (using
an exogenous marker) as a reference suggest that either one or both estimates lose precision in
our elderly cohort. Several potential contributing factors should be considered as possible
explanations.
First is a possible systematic overestimation of GFR using eGFRcr in our cohort. In our
cohort, age was associated with reclassification of creatinine-based CKD status using cystatin
C, whereas male sex was associated with decreased likelihood of reclassification. Prior investi-
gators have suggested using age, cardiovascular disease, diabetes, hypertension, obesity, and
smoking to identify patients who may have occult CKD not identified using eGFRcr alone and
therefore warrant eGFRcys assessment.[38] With the exception of diabetes, our data is consis-
tent with these prior findings. An increased prevalence of sarcopenia with age may be contrib-
uting to lower-than-expected serum creatinine independent of renal function and lead to the
large discrepancy between eGFRcr and eGFRcys that we observed.
The other possibility is that eGFRcys systematically underestimates GFR in the NOMAS
cohort instead of (or in addition to) the hypothesized mechanism above. Age, weight, and
smoking are known to be associated with increased cystatin C levels even after controlling for
creatinine clearance.[39] Consistent with this, these patient characteristics were all associated
with increased reclassification in our cohort supporting the notion that a high prevalence of
obesity and smoking would limit the ability of eGFRcys to accurately identify CKD in older
cohorts.
Finally, currently available cystatin C assays vary significantly, underscoring the need for
the ongoing development of reference material for cystatin C assays intended to improve this
problem.[40–46] In contrast to the CKD-EPI group, which used a Siemens Dade Behring
Nephelometer traceable to IFCC/IRMM reference materials, we used a Roche assay also
standardized against ERM-DA471/IFCC reference material. Despite this difference, the cysta-
tin C values we observed are quite plausible. The mean serum cystatin C was 1.4mg/L in the
CKD-EPI study development/internal validation cohort.[10] Further, a previous investigation
on cystatin C concentration in healthy elderly subjects (age�65 years) in Britain found a
mean cystatin C of 1.48mg/L in females and 1.53mg/L in males, also similar to our observed
mean of 1.4mg/L.[47] Other prior studies focusing elderly participants have demonstrated var-
iable mean cystatin C values, ranging from 1.14–1.44 mg/L.[21, 32–34] While it is certainly
possible that our cystatin C assay may be less reliable than expected, considering that our test-
ing utilized a commercially-available cystatin C assay, these discrepancies underscore the need
for further studies including measured GFR data to determine their etiology in addition to the
need for better cystatin assay standardization. This uncertainty should similarly be considered
when interpreting GFR estimates that utilize both creatinine and cystatin (eGFRcr-cys), and
additional investigation is needed to determine whether the use of both biomarkers together
improves the accuracy of GFR estimates in this population.
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Grubb, et al have proposed an alternative, assay-independent, cystatin-based eGFR equa-
tion (“CAPA”) developed using Swedish, Japanese, and Dutch cohorts.[24] However, given
the limited demographic subgroups in which this equation was developed, its applicability to a
broad section of the United States population remains uncertain. Similarly, the BIS (Berlin Ini-
tiative Study) equations designed for use in the elderly included only subjects living in Berlin,
Germany.[21] Domestic initiatives are warranted to better address the need for improved GFR
assessment in the United States, particularly in non-White populations.
Our findings have significant implications for clinical practice because the discrepant CKD
categorizations would warrant different dose adjustments and carry significantly different
prognostic implications. Currently, clinicians routinely receive eGFR data alongside serum
creatinine results. Our observations suggest that these data could be misleading in populations
similar to ours, potentially leading to inappropriate decisions regarding drug dosing, drug
safety, risk stratification, and eligibility for advanced therapeutics. Accurate GFR ascertain-
ment is critical for accurate dosing of medications cleared by the kidney, especially among
elderly patients already at higher risk of polypharmacy-associated complications. This under-
scores the need for further study of the performance of different methods of GFR estimation
in older, diverse populations.
In addition to changing the need for evaluation of CKD-associated complications including
anemia and bone disease, accurately identifying decreased GFR can help clinicians better
assess the contribution of CKD to patient outcomes such as cardiovascular events and mortal-
ity. Discrepant estimates using creatinine and cystatin may even be a marker for sarcopenia in
the elderly and thus further inform the clinical care of these patients.[48] Finally, the timely
CKD diagnosis and early referral to a nephrologist have been associated with improved out-
comes.[49]
Our study confirms previous findings of significantly discrepant CKD diagnosis in elderly
patients, but in a larger multiethnic cohort. The strengths of our study include a large sample
size and diverse population. Limitations include the lack of measured GFR testing, as detailed
above. These data would allow us to determine whether the differences between eGFRcr and
eGFRcys result from lack of precision of one or both GFR estimates. Additionally, we lack
information regarding albuminuria, an important component of CKD diagnosis, classifica-
tion, and risk prediction, and our cross-sectional design relies on a single simultaneous creati-
nine and cystatin measurements for each participant. It should also be noted that the use of
concordance of eGFR<60ml/min/1.73m2 (i.e. the established eGFR-based threshold for CKD
diagnosis) as a primary endpoint is somewhat arbitrary, although the large differences in GFR
estimates we observed emphasize the clinical importance of these findings. Further studies
investigating differences in morbidity and mortality, as well as the development of clinically
relevant kidney disease, among our participants whose CKD status was reclassified are also
warranted, as the value of precise GFR estimates may not necessarily translate to improved
prediction of adverse outcomes such as progression to end-stage renal disease or incidence of
cardiovascular events.
Conclusions
In a large, racially/ethnically diverse, elderly population, we observed a dramatic increase in
the prevalence of CKD and a significant amount of reclassification of CKD diagnosis when
using cystatin C- rather than creatinine-based estimates of GFR. Given the aging of the popu-
lation and the known associations between CKD and adverse cardiovascular events, our find-
ings suggest that urgent further study is needed to clarify the accuracy of different methods of
GFR estimation in the elderly. Improving GFR estimation in elderly patients can help identify
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unrecognized CKD, prevent CKD misdiagnosis, and promote management of CKD-associated
complications at an earlier stage.
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